How to evaluate a TrypLE alternative for biopharmaceutical manufacturing

Cell dissociation may appear to be a routine operation in mammalian cell culture. In biopharmaceutical manufacturing, however, its impact extends far beyond cell detachment. Whether working with production cell lines, stem cells, viral vector processes, or advanced therapy medicinal products (ATMPs), cell dissociation can directly influence:

• Cell viability
• Recovery/Yield
• Growth characteristics
• Phenotype stability
• Process reproducibility

Why biopharma companies are looking beyond traditional cell dissociation reagents
Recombinant cell dissociation enzymes have largely replaced animal-derived trypsin in biopharmaceutical manufacturing. Trypsin-like enzymes such as TrypLE^TM1 have become the industry standard as they are animal-origin free, consistent, gentle on cells, and easy to integrate into established cell culture workflows.

However, the requirements for cell culture raw materials are evolving. With cell therapies, viral vectors, vaccines, and other advanced biopharmaceuticals moving toward clinical and commercial manufacturing, therapy developers increasingly prioritize quality, comprehensive documentation, and supply chain reliability in addition to performance. Four developments are shaping this change.

• Rising regulatory expectations:  Regulators expect manufacturers to understand and control the raw materials used in their processes. Greater emphasis on product specifications, robust quality systems, traceability, and accessible documentation is raising supplier qualification requirements. Manufacturers therefore expect greater transparency regarding production processes, raw material origin, analytical testing, and quality oversight.

• Growth of cell and gene therapies: Advanced therapy medicinal products (ATMP) manufacturing often involves sensitive cell types and tightly controlled processes. Process consistency and reproducibility are equally important as dissociation performance, while the selected reagent should be suitable for both, process development and GMP manufacturing.

• Supply chain resilience: Recent disruptions across the life sciences industry have made supply security a practical concern. Biopharmaceutical manufacturers increasingly seek transparency into where critical materials are produced, how manufacturing processes are controlled, and whether suppliers can reliably meet long-term demand.

• Moving from R&D to GMP: Changing a critical material during scale-up will lead to additional qualification work. Products that provide comparable specifications and performance across development and GMP-grades can help reduce process-transfer risk and simplify qualification activities. CellTrypase is available in both R&D and GMP grades, with both quality grades manufactured using the same process and meeting identical product specifications. These points broaden the evaluation beyond a simple performance check.

Instead of asking only: Can this enzyme detach my cells? It is worth asking: Can this enzyme support my process from early development through GMP manufacturing with the quality, traceability, and documentation required for long-term success?

Five questions can help structure that evaluation.

1. Is the enzyme recombinant and animal-origin free?
Animal-origin free ancillary materials have become standard expectations in biopharmaceutical manufacturing. Recombinant fungal trypsin-like enzymes provide several advantages compared with animal-derived trypsin:

• Reduced risk of animal-derived contaminants

• Improved batch-to-batch consistency

• Better support for regulatory compliance

• Simplified qualification in GMP environments

Today, most manufacturers would consider this a prerequisite rather than a differentiator. The more relevant question is what comes next.

2. Is product purity clearly defined?
Many enzyme suppliers describe their products as "high purity". The important question is: How is purity defined and how is it controlled?

For biopharmaceutical manufacturing, product specifications should be transparent and measurable. A well-defined purity specification helps minimize variability and provides confidence that materials used during process development remain consistent with future manufacturing lots. CellTrypase is released with a defined purity specification of ≥95% determined by HPLC analysis. Purity is defined as a release-relevant specification rather than a general quality claim, supporting reproducibility and consistency across cell culture workflows.

3. Can the enzyme be integrated into existing cell culture protocols?
Introducing a new raw material should not require re-designing an established process. An ideal recombinant cell dissociation enzyme should:

• Fit existing workflows

• Require minimal retraining

• Preserve cell quality

• Avoid additional process steps

Most recombinant fungal trypsin-like enzymes can be used without specific inhibitors because residual activity is sufficiently reduced by dilution in medium or buffer. CellTrypase is supplied as a sterile-filtered liquid formulation and can be used as a direct replacement for commonly used recombinant cell dissociation enzymes.

4. How is the product manufactured and supplied?
As supply chain resilience becomes a strategic priority, manufacturers increasingly evaluate where and how critical raw materials are produced. Important questions include:

• Who manufactures the enzyme?

• Is the process fully traceable?

• Are documentation packages available?

• Is supply dependent on multiple external suppliers?

For GMP workflows, these factors are often just as important as biological performance. Materials produced through controlled, fully traceable manufacturing processes can help streamline supplier qualification, audits, and regulatory interactions. CellTrypase is manufactured in-house in Germany using a proprietary GMP-compliant process, ensuring full supply chain control and traceability.

5. Is the product suitable for GMP manufacturing?
Many reagents perform well in research environments. Fewer are specifically designed to also support regulated manufacturing. When evaluating a cell dissociation enzyme, consider:

• Availability of GMP-grade material

• Regulatory support documentation

• Quality management system

• Change control processes

• Traceability and lot documentation

CellTrypase GMP-grade is manufactured under an EXCiPACT-certified quality system for pharmaceutical excipients and is supported by audit-ready documentation and full traceability. An important advantage is that both R&D-grade and GMP-grade products are manufactured using the same production process and meet identical specifications, helping to simplify process transfer from development to manufacturing. CellTrypase is also supported by a dedicated Qualification and Change Guidance document designed to help manufacturers assess qualification requirements and facilitate a smooth, compliant transition from existing trypsin-like enzymes.

These five criteria provide a broader framework for evaluating recombinant cell dissociation enzymes. However, quality, traceability, and GMP support only add value if biological performance is maintained.

Does Greater Process Control Require a Trade-Off in Performance?
In studies with commonly used biopharmaceutical production cell lines, CellTrypase demonstrated comparable or better performance than an established recombinant trypsin-like enzyme. Dissociation time, viability, yield, and population doubling remained comparable over multiple passages.

CellTrypase was also evaluated with human induced pluripotent stem cells (iPSCs), enabling effective dissociation while maintaining high cell viability and pluripotency marker expression.

These findings demonstrate that robust dissociation performance go hand in hand with defined product quality, traceability, and process control.

Performance Is Essential, but It Is Not the Only Differentiator
Biological performance is an essential part of enzyme selection, but it is not the only consideration. For long-term use in regulated biopharmaceutical workflows, manufacturers should also evaluate:

• Defined quality specifications

• Manufacturing and supply chain control

• Regulatory readiness and qualification support

• Traceability and documentation

• Suitability from process development through GMP manufacturing

For cell therapies, viral vectors, vaccines, and other advanced biopharmaceuticals, these factors can support process robustness and facilitate qualification.

The key question is therefore not only: Can this enzyme detach my cells?

It is also: Can this enzyme support my process from development through GMP manufacturing with consistent quality, traceability, reliable supply and appropriate regulatory support?

Conclusion
Choosing an alternative cell dissociation enzyme requires more than comparing detachment performance. Manufacturers should also consider recombinant and animal-origin free production, defined purity, workflow compatibility, manufacturing traceability, supply reliability, and regulatory support.

CellTrypase combines established cell dissociation performance with a defined purity specification of ≥95% by HPLC, in-house GMP-compliant manufacturing, and full traceability. Dedicated qualification and change guidance further supports customers in evaluating and implementing CellTrypase in regulated biopharmaceutical workflows. This gives manufacturers a practical option for building robust, scalable cell culture processes from development through GMP manufacturing. Get your free sample here.

 ¹ TrypLE™ is a registered trademark owned by Thermo Fisher Scientific Inc